Guide

Non-estrogen medication for hot flashes: understand the treatment families

Separate antidepressant medicines, neurokinin-targeted treatments, other prescriptions and evidence-based non-drug support without ranking them for an individual.

Guide

Fezolinetant and liver monitoring: understand the responsibility behind the tests

What Veozah's current boxed warning adds to a hot-flash treatment discussion, and why a laboratory order needs a clear review and response process.

Guide

Lynkuet vs Veozah: a guide to comparing the evidence

Compare the questions each product raises, read the trial limits and prepare for a discussion about treatment and follow-up.

Guide

Prepare a nonhormonal menopause visit around the result that matters to you

Bring symptom priorities, previous treatment experience and practical follow-up questions without trying to choose a prescription from an online checklist.

Guide

Paroxetine’s Menopause Trials: Reading Hot-Flash and Sleep Outcomes Together

Two placebo-controlled trials support a specific hot-flash benefit, while a secondary analysis found modest improvements in symptom-attributed awakenings and sleep duration. Those findings answer a different question from fezolinetant’s research program.

Guide

SKYLIGHT 1: Fezolinetant’s Symptom Effects and Evolving Liver-Safety Evidence

The 527-participant trial established a placebo-adjusted symptom benefit over 12 weeks. Its findings answer a different question from paroxetine’s sleep analyses—and must now be read alongside VEOZAH’s boxed liver warning.